Research programme: deubiquitinating enzyme inhibitors - MISSION Therapeutics

Drug Profile

Research programme: deubiquitinating enzyme inhibitors - MISSION Therapeutics

Alternative Names: Deubiquitylating enzyme inhibitors - MISSION Therapeutics; DUB inhibitors - MISSION Therapuetics

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator MISSION Therapeutics
  • Class Small molecules
  • Mechanism of Action Deubiquitinating enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Neurodegenerative disorders; Ovarian cancer

Most Recent Events

  • 05 Dec 2016 Deubiquitinating enzyme inhibitors are still in Early Research stage for Cancer in USA
  • 05 Dec 2016 Early research in Neurodegenerative disorders in USA (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top